AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35361348 — intervention group
Group type: COMPARATOR
Intervention: Control sleep (9 hour sleep opportunity)
Number of subjects: 12
Study 33241466 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% levofloxacin with 0.1% fluorometholone administered four times a day
Number of subjects: 19
Study 33241466 — intervention group
Group type: COMPARATOR
Intervention: sixfold dilution of polyvinyl alcohol iodine (PAI) solution with 0.1% fluorometholone four times a day
Number of subjects: 19
Study 35121271 — intervention group
Group type: EXPERIMENTAL
Intervention: Face to face (FtF) therapy
Number of subjects: 101
Study 35121271 — intervention group
Group type: COMPARATOR
Intervention: Digital (dCBT-I) therapy
Number of subjects: 101
Study 35121271 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FtF and dCBT-I
Number of subjects: 101
Study 33303654 — intervention group
Group type: EXPERIMENTAL
Intervention: RAAS inhibitors (RAASi)
Number of subjects: 576
Study 33303654 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 576
Study 33438897 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive result studies (185 studies, 64.2%)
Number of subjects: 288
Study 33438897 — intervention group
Group type: COMPARATOR
Intervention: Negative result studies (103 studies, 35.8%)
Number of subjects: 288
Study 33438897 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies with larger sample sizes
Number of subjects: 288
Study 33438897 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies classified as positive result
Number of subjects: 288
Study 33023491 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.04 mg/kg neostigmine
Number of subjects: 132
Study 33023491 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 mg/kg neostigmine
Number of subjects: 132
Study 33023491 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 132
Study 35685192 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap with chorion membrane (CAF+CM)
Number of subjects: 8
Study 35685192 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap with connective tissue graft (CAF+CTG)
Number of subjects: 8
Study 34551959 — intervention group
Group type: EXPERIMENTAL
Intervention: FeverPAIN ≥4
Number of subjects: 565
Study 34551959 — intervention group
Group type: EXPERIMENTAL
Intervention: Centor ≥3
Number of subjects: 565
Study 32818625 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline genetic factors and polygenic/multifactorial risk scores
Number of subjects: 0
Study 32818625 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare high-penetrance variants
Number of subjects: 0
Study 32818625 — intervention group
Group type: EXPERIMENTAL
Intervention: Telomere length and mitochondrial DNA copy number
Number of subjects: 0
Study 32818625 — intervention group
Group type: EXPERIMENTAL
Intervention: Common variants
Number of subjects: 0
Study 32818625 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetics of pancreatic neuroendocrine tumors (PNET)
Number of subjects: 0
Study 35700594 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (1.5 g)
Number of subjects: 24
Study 35700594 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1.5 g of starch)
Number of subjects: 24
Study 37227388 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10137
Study 37227388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10137
Study 34303491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative HPI-guided care
Number of subjects: 60
Study 34303491 — intervention group
Group type: COMPARATOR
Intervention: Standard haemodynamic care
Number of subjects: 60
Study 32925975 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncorrected visual impairment (VA ≤ 6/12)
Number of subjects: 4985
Study 32925975 — intervention group
Group type: EXPERIMENTAL
Intervention: Presenting visual impairment (VA ≤ 6/12)
Number of subjects: 4985
Study 32925975 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-corrected visual impairment (VA ≤ 6/12)
Number of subjects: 4985
Study 32925975 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractive error as a cause of impaired vision
Number of subjects: 4985
Study 32925975 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopia (≤ -0.5 D)
Number of subjects: 4985
Study 32925975 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperopia (≥ +2.0 D)
Number of subjects: 4985
Study 32925975 — intervention group
Group type: EXPERIMENTAL
Intervention: Astigmatism (≥ 0.75 D)
Number of subjects: 4985
Study 35727442 — intervention group
Group type: EXPERIMENTAL
Intervention: ProxiMAX randomization
Number of subjects: 0
Study 35727442 — intervention group
Group type: EXPERIMENTAL
Intervention: MAX randomization
Number of subjects: 0
Study 33608712 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for 5 years
Number of subjects: 1204
Study 33608712 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen for 2 years followed by Anastrozole for 3 years
Number of subjects: 1204
Study 33608712 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM-50 analysis
Number of subjects: 1204
Study 33104739 — intervention group
Group type: EXPERIMENTAL
Intervention: Labelled scenarios
Number of subjects: 0
Study 33104739 — intervention group
Group type: COMPARATOR
Intervention: Descriptive scenarios
Number of subjects: 0
Study 33104739 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence
Number of subjects: 0
Study 33104739 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction
Number of subjects: 0
Study 33104739 — intervention group
Group type: EXPERIMENTAL
Intervention: Predisposition to seek healthcare
Number of subjects: 0
Study 33104739 — intervention group
Group type: EXPERIMENTAL
Intervention: Attributing illness to bad luck
Number of subjects: 0
Study 33104739 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about the health condition
Number of subjects: 0
Study 35484039 — intervention group
Group type: EXPERIMENTAL
Intervention: MucoRice-CTB vaccine (6-g dose)
Number of subjects: 9
Study 33846198 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Number of subjects: 0
Study 33846198 — intervention group
Group type: COMPARATOR
Intervention: standard of care (SOC) with chemotherapy
Number of subjects: 0
Study 35532915 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound intervention with digital scales, electronic pill bottles, and regret lottery incentives ($1.40 expected daily value)
Number of subjects: 552
Study 35532915 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 552
Study 35532915 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound intervention
Number of subjects: 552
Study 33670797 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term midwife-led breastfeeding support
Number of subjects: 1080
Study 33670797 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial support
Number of subjects: 1080
Study 36352602 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga as a complementary treatment for epilepsy
Number of subjects: 15
Study 36352602 — intervention group
Group type: COMPARATOR
Intervention: Studies describing knowledge, attitude, influence, and practice of yoga in epilepsy
Number of subjects: 15
Study 35965789 — intervention group
Group type: EXPERIMENTAL
Intervention: Yun-type training
Number of subjects: 150
Study 35965789 — intervention group
Group type: COMPARATOR
Intervention: PFMT
Number of subjects: 150
Study 33152686 — intervention group
Group type: EXPERIMENTAL
Intervention: Light exposure and sleep hygiene intervention (INT)
Number of subjects: 20
Study 33152686 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 20
Study 35274222 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg warfarin
Number of subjects: 50
Study 35274222 — intervention group
Group type: COMPARATOR
Intervention: 3 mg warfarin
Number of subjects: 50
Study 33889958 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted plasma LRG1 levels (associated with rs4806985 variant)
Number of subjects: 3694
Study 33889958 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis
Number of subjects: 3694
Study 35271811 — intervention group
Group type: EXPERIMENTAL
Intervention: unilateral intravitreal AAV2(Y444,500,730F)‐P1ND4v2 injection (higher doses)
Number of subjects: 28
Study 35271811 — intervention group
Group type: COMPARATOR
Intervention: unilateral intravitreal AAV2(Y444,500,730F)‐P1ND4v2 injection (lower doses)
Number of subjects: 28
Study 35271811 — intervention group
Group type: EXPERIMENTAL
Intervention: unilateral intravitreal AAV2(Y444,500,730F)‐P1ND4v2 injection
Number of subjects: 28
Study 33017530 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% baking soda toothpaste
Number of subjects: 319
Study 33017530 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% baking soda toothpaste
Number of subjects: 319
Study 33017530 — intervention group
Group type: COMPARATOR
Intervention: Fluoride toothpaste control
Number of subjects: 319
Study 36180152 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization with movement (MWM) adductor stretch
Number of subjects: 54
Study 36180152 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release
Number of subjects: 54
Study 36180152 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional stretching
Number of subjects: 54
Study 36180152 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study 32778521 — intervention group
Group type: EXPERIMENTAL
Intervention: HA‐WBRT (30 Gy/10 fractions)
Number of subjects: 34
Study 34274079 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg) given 45 minutes before training
Number of subjects: 30
Study 34274079 — intervention group
Group type: COMPARATOR
Intervention: Control (no caffeine)
Number of subjects: 30
Study 32032307 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture-negative late-onset sepsis (LOS)
Number of subjects: 1505
Study 36029771 — intervention group
Group type: EXPERIMENTAL
Intervention: Human-derived fortifier (H2MF)
Number of subjects: 30
Study 36029771 — intervention group
Group type: COMPARATOR
Intervention: Bovine-derived human milk fortifier (BHMF)
Number of subjects: 30
Study 36029771 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's own milk (MOM)
Number of subjects: 30
Study 36029771 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidative stress (urinary F2‐isoprostanes)
Number of subjects: 30
Study 32052214 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable cabotegravir (CAB LA)
Number of subjects: 0
Study 35799365 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 8% Patch (C8P)
Number of subjects: 11
Study 35799365 — intervention group
Group type: COMPARATOR
Intervention: Control low dose Capsaicin 0.025% patch (CON)
Number of subjects: 11
Study 32692284 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for overall survival (OS) prediction
Number of subjects: 1787
Study 32692284 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for cancer-specific survival (CSS) prediction
Number of subjects: 1787
Study 32692284 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram prediction
Number of subjects: 1787
Study 32692284 — intervention group
Group type: EXPERIMENTAL
Intervention: New predictive model
Number of subjects: 1787
Study 34009520 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser with low fluence and low density (800-µm tip, 5% density, 10 mJ fluence, single pass)
Number of subjects: 40
Study 33567505 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher glycine concentrations
Number of subjects: 151
Study 33567505 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher linoleic acid concentrations
Number of subjects: 151
Study 33567505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose concentrations
Number of subjects: 151
Study 33567505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphingomyelins (C32:2, C38:1) concentrations
Number of subjects: 151
Study 32208844 — intervention group
Group type: EXPERIMENTAL
Intervention: Coiling
Number of subjects: 0
Study 32208844 — intervention group
Group type: COMPARATOR
Intervention: Clipping
Number of subjects: 0
Study 36285763 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma (CCP)
Number of subjects: 394
Study 36285763 — intervention group
Group type: COMPARATOR
Intervention: Imported doses from Héma-Québec
Number of subjects: 394
Study 36285763 — intervention group
Group type: COMPARATOR
Intervention: Transferred doses between CBS regional distribution centers
Number of subjects: 394
Study 36285763 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusions at hubs and spoke sites
Number of subjects: 394
Study 36285763 — intervention group
Group type: EXPERIMENTAL
Intervention: Equitable allocation model
Number of subjects: 394
Study 35010391 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Acceptance‐Commitment (MAC) program (n = 20; 7 group sessions, 60 min each)
Number of subjects: 40
Study 35010391 — intervention group
Group type: COMPARATOR
Intervention: Active control group (n = 20; 7 group sessions, 60 min each)
Number of subjects: 40
Study 35922380 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive VR‐ABM
Number of subjects: 120
Study 35922380 — intervention group
Group type: COMPARATOR
Intervention: Desktop VR‐ABM
Number of subjects: 120
Study 35922380 — intervention group
Group type: COMPARATOR
Intervention: Immersive VR‐game
Number of subjects: 120
Study 33158824 — intervention group
Group type: EXPERIMENTAL
Intervention: e-PROMs data capture and feedback
Number of subjects: 63
Study 34850776 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel irradiation stent (NIS)
Number of subjects: 94
Study 34850776 — intervention group
Group type: COMPARATOR
Intervention: Conventional irradiation stent (CIS)
Number of subjects: 94
Study 34101389 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin 40 mg/m2
Number of subjects: 77
Study 34101389 — intervention group
Group type: COMPARATOR
Intervention: Three-weekly cisplatin 100 mg/m2
Number of subjects: 77
Study 34101389 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 77
Study 34373299 — intervention group
Group type: EXPERIMENTAL
Intervention: Perx app
Number of subjects: 124
Study 34373299 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 124
Study 35954612 — intervention group
Group type: EXPERIMENTAL
Intervention: Hedonic aroma (essential oils) during chemotherapy (inhalation during T1, T2, T3)
Number of subjects: 112
Study 35954612 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 112
Study 33619780 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g cutaneous foam (Cal/BD foam)
Number of subjects: 3
Study 33619780 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol/betamethasone dipropionate foam (Cal/BD foam)
Number of subjects: 3
Study 32142039 — intervention group
Group type: EXPERIMENTAL
Intervention: IC-8 Group (monofocal 1-piece Tecnis Z B00 IOL in dominant eye and IC-8 IOL in nondominant eye)
Number of subjects: 38
Study 32142039 — intervention group
Group type: COMPARATOR
Intervention: Symfony Group (Tecnis Symfony IOL in both eyes)
Number of subjects: 38
Study 34785366 — intervention group
Group type: EXPERIMENTAL
Intervention: anodal tDCS (a-tDCS)
Number of subjects: 48
Study 34785366 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS (s-tDCS)
Number of subjects: 48
Study 34376257 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated malaria prevention methods (including insecticide-treated nets, house screening, indoor residual spraying)
Number of subjects: 31
Study 34376257 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated malaria prevention methods
Number of subjects: 31
Study 36113498 — intervention group
Group type: COMPARATOR
Intervention: CRT (78 Gy in 39 fractions over 7.8 weeks or 62 Gy in 20 fractions over 4 weeks)
Number of subjects: 874
Study 36113498 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT (36.25 Gy in five fractions over 1-2 weeks)
Number of subjects: 874
Study 33314699 — intervention group
Group type: EXPERIMENTAL
Intervention: ACPA-positive patients
Number of subjects: 606
Study 33177798 — intervention group
Group type: EXPERIMENTAL
Intervention: SPMC ½ dose × 2
Number of subjects: 78
Study 33177798 — intervention group
Group type: EXPERIMENTAL
Intervention: SPMC 1 dose × 2
Number of subjects: 78
Study 33177798 — intervention group
Group type: COMPARATOR
Intervention: PEG
Number of subjects: 78
Study 35666526 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy with standard care
Number of subjects: 408
Study 35607733 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential injection of 1.5 mL of 0.5% hyperbaric bupivacaine with 15 μg of fentanyl followed by 1.5 mL of 0.5% isobaric bupivacaine (HIB group)
Number of subjects: 50
Study 35607733 — intervention group
Group type: COMPARATOR
Intervention: 3 mL of 0.5% hyperbaric bupivacaine mixed with 15 μg of fentanyl citrate (HB group)
Number of subjects: 50
Study 33307206 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga program (12-week, 2x weekly/90-minute sessions)
Number of subjects: 57
Study 33307206 — intervention group
Group type: COMPARATOR
Intervention: Education control group (1x weekly/60-minute lectures)
Number of subjects: 57
Study 32460577 — intervention group
Group type: EXPERIMENTAL
Intervention: TIM-1 levels (third tertile)
Number of subjects: 4591
Study 32460577 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian Randomization analysis
Number of subjects: 4591
Study 35101266 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-dose schedule (0–7–21–360)
Number of subjects: 150
Study 35101266 — intervention group
Group type: COMPARATOR
Intervention: Three-dose schedule (days 0–30–360)
Number of subjects: 150
Study 35101266 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-dose schedule (0–30–90–360)
Number of subjects: 150
Study 34402161 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10142
Study 34402161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10142
Study 35247147 — intervention group
Group type: EXPERIMENTAL
Intervention: Family support-based intervention via a mobile application by pharmacists
Number of subjects: 157
Study 35247147 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 157
Study 33558076 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 60
Study 33558076 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 60
Study 35172436 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) for 3 days (Group A, n=138)
Number of subjects: 250
Study 35172436 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B, n=112)
Number of subjects: 250
Study 32420337 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer group-based training
Number of subjects: 60
Study 32420337 — intervention group
Group type: COMPARATOR
Intervention: Routine care by nurse (Control)
Number of subjects: 60
Study 35139802 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of resistance plus nerve stimulation (LOR + NS)
Number of subjects: 100
Study 35139802 — intervention group
Group type: COMPARATOR
Intervention: Loss of resistance alone (LOR-alone)
Number of subjects: 100
Study 33414239 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg twice daily for 16 weeks
Number of subjects: 346
Study 33414239 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily for 16 weeks
Number of subjects: 346
Study 33414239 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg twice daily for 12 months
Number of subjects: 346
Study 33414239 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily for 12 months
Number of subjects: 346
Study 35361556 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (12-month duration, delivered twice weekly for the first 12 weeks, then once weekly; included cardiovascular, strength, balance, and flexibility exercises)
Number of subjects: 102
Study 35361556 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 102
Study 35361556 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical activity intervention)
Number of subjects: 102
Study 35150494 — intervention group
Group type: EXPERIMENTAL
Intervention: Education during pregnancy and listening to classical music
Number of subjects: 198
Study 35150494 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 198
Study 32538577 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid-TTI group (N=150)
Number of subjects: 450
Study 32538577 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-rigid TTI group (N=150)
Number of subjects: 450
Study 32538577 — intervention group
Group type: COMPARATOR
Intervention: Non-TTI group (N=150)
Number of subjects: 450
Study 37816915 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation (3 W, 150 mJ, 20 Hz, 100 μs) after FM-SRP
Number of subjects: 60
Study 37816915 — intervention group
Group type: COMPARATOR
Intervention: FM-SRP
Number of subjects: 60
Study 33625584 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone 100 mg
Number of subjects: 22
Study 33625584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 32716326 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis (2% for 20 minutes at 1mA/min) combined with exercises (1 hour, three times a week for three months)
Number of subjects: 30
Study 32716326 — intervention group
Group type: COMPARATOR
Intervention: Control group (exercises only, same duration and frequency)
Number of subjects: 30
Study 34580251 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous left atrial appendage occlusion (LAAO)
Number of subjects: 980
Study 34580251 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulation (OAC) therapy
Number of subjects: 980
Study 33899580 — intervention group
Group type: COMPARATOR
Intervention: fenobam
Number of subjects: 20
Study 36158133 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision health education guidance after ESWL treatment
Number of subjects: 104
Study 36158133 — intervention group
Group type: COMPARATOR
Intervention: Control group (only informed of precautions after lithotripsy)
Number of subjects: 104
Study 36158133 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete compliance group (n = 64)
Number of subjects: 104